OpGen Inc (NASDAQ:OPGN) was one of the many companies to have come into focus among investors yesterday and it was evident from the price action in the company’s stock. The stock ended the day with gains of as much as 6.5% after the company made a major announcement.
OpGen announced yesterday that it had been granted the coveted clearance by the United States Food and Drug Administration by way of which the company will be able to market its product Acuitas AMR Gene Panel. However, that is not all. The company also announced that it was working on its preparations for launching the product in the United States fairly quickly.
The product is an innovative one and one that the company believes is going to be quite beneficial to clinics. The company claims that the Acuitas AMR Gene Panel could prove to be a highly beneficial diagnostic product since it is going to help in informing clinicians about antimicrobial resistance and about the suitable antibiotic treatments.
It goes without saying that the latest development was a significant one for OpGen and the enthusiasm of the investors are perhaps not misplaced. At this point it might be a good idea to keep the stock in your watch lists.
